Literature DB >> 19116244

SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.

Sanna Kaikkonen1, Tiina Jääskeläinen, Ulla Karvonen, Miia M Rytinki, Harri Makkonen, Daniel Gioeli, Bryce M Paschal, Jorma J Palvimo.   

Abstract

The acceptor sites for small ubiquitin-like modifier (SUMO) are conserved in the N-terminal domains of several nuclear receptors. Here, we show that androgens induce rapid and dynamic conjugation of SUMO-1 to androgen receptor (AR). Nuclear import of AR is not sufficient for SUMOylation, because constitutively nuclear apo-ARs or antagonist-bound ARs are only very weakly modified by SUMO-1 in comparison with agonist-bound ARs. Of the SUMO-specific proteases (SENP)-1, -2, -3, -5, and -6, only SENP1 and SENP2 are efficient in cleaving AR-SUMO-1 conjugates in intact cells and in vitro. Both SENP1 and -2 are nuclear and found at sites proximal to AR. Their expression promotes AR-dependent transcription, but in a promoter-selective fashion. SENP1 and -2 stimulated the activity of holo-AR on compound androgen response element-containing promoters. The effects of SENP1 and -2 on AR-dependent transcription were dependent on catalytic activity and required intact SUMO acceptor sites in AR, indicating that their coactivating effects are mainly due to their direct isopeptidase activity on holo-AR. In prostate cancer cells, ectopic expression of SENP1, but not that of SENP2, increased the transcription activity of endogenous AR. Silencing of SENP1 attenuated the expression of several AR target genes and blunted androgen-stimulated growth of LNCaP cells. Our results indicate that SENP1 reverses the ligand-induced SUMOylation of AR and helps fine tune the cellular responses to androgens in a target promoter-selective manner.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19116244      PMCID: PMC5428156          DOI: 10.1210/me.2008-0219

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  87 in total

Review 1.  PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription.

Authors:  J J Palvimo
Journal:  Biochem Soc Trans       Date:  2007-12       Impact factor: 5.407

Review 2.  Concepts in sumoylation: a decade on.

Authors:  Ruth Geiss-Friedlander; Frauke Melchior
Journal:  Nat Rev Mol Cell Biol       Date:  2007-12       Impact factor: 94.444

3.  The nucleoporin RanBP2 has SUMO1 E3 ligase activity.

Authors:  Andrea Pichler; Andreas Gast; Jacob S Seeler; Anne Dejean; Frauke Melchior
Journal:  Cell       Date:  2002-01-11       Impact factor: 41.582

4.  ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation.

Authors:  N Kotaja; S Aittomäki; O Silvennoinen; J J Palvimo; O A Jänne
Journal:  Mol Endocrinol       Date:  2000-12

5.  SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1.

Authors:  Toula Bouras; Maofu Fu; Anthony A Sauve; Fang Wang; Andrew A Quong; Neil D Perkins; Ronald T Hay; Wei Gu; Richard G Pestell
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

6.  PIASxalpha differentially regulates the amplitudes of transcriptional responses following activation of the ERK and p38 MAPK pathways.

Authors:  Shen-Hsi Yang; Andrew D Sharrocks
Journal:  Mol Cell       Date:  2006-05-19       Impact factor: 17.970

7.  Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer.

Authors:  Liliana A Ponguta; Christopher W Gregory; Frank S French; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2008-05-29       Impact factor: 5.157

8.  Potentiation of glucocorticoid receptor transcriptional activity by sumoylation.

Authors:  Yves Le Drean; Nathalie Mincheneau; Pascale Le Goff; Denis Michel
Journal:  Endocrinology       Date:  2002-09       Impact factor: 4.736

9.  The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor.

Authors:  H Poukka; U Karvonen; N Yoshikawa; H Tanaka; J J Palvimo; O A Jänne
Journal:  J Cell Sci       Date:  2000-09       Impact factor: 5.285

10.  SUSP1 antagonizes formation of highly SUMO2/3-conjugated species.

Authors:  Debaditya Mukhopadhyay; Ferhan Ayaydin; Nagamalleswari Kolli; Shyh-Han Tan; Tadashi Anan; Ai Kametaka; Yoshiaki Azuma; Keith D Wilkinson; Mary Dasso
Journal:  J Cell Biol       Date:  2006-09-25       Impact factor: 10.539

View more
  52 in total

Review 1.  Human pathogens and the host cell SUMOylation system.

Authors:  Peter Wimmer; Sabrina Schreiner; Thomas Dobner
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Role of the BCA2 ubiquitin E3 ligase in hormone responsive breast cancer.

Authors:  Angelika M Burger; Fathima Kona; Yutaka Amemiya; Yuguang Gao; Stephanie Bacopulos; Arun K Seth
Journal:  Open Cancer J       Date:  2010

3.  SUMO-specific protease 2 in Mdm2-mediated regulation of p53.

Authors:  M Jiang; S-Y Chiu; W Hsu
Journal:  Cell Death Differ       Date:  2010-12-24       Impact factor: 15.828

4.  Sumoylation of SAE2 C terminus regulates SAE nuclear localization.

Authors:  Khue Truong; Terry D Lee; Baozong Li; Yuan Chen
Journal:  J Biol Chem       Date:  2012-10-24       Impact factor: 5.157

5.  Assays for investigating deSUMOylation enzymes.

Authors:  Ikenna G Madu; Yuan Chen
Journal:  Curr Protoc Mol Biol       Date:  2012-07

Review 6.  Molecular pathogenesis and progression of prostate cancer.

Authors:  Randy Schrecengost; Karen E Knudsen
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

7.  Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer.

Authors:  Karen E Knudsen; William Kevin Kelly
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05

8.  Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.

Authors:  Päivi Sutinen; Vesa Rahkama; Miia Rytinki; Jorma J Palvimo
Journal:  Mol Endocrinol       Date:  2014-08-15

Review 9.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

10.  Identification and characterization of a new chemotype of noncovalent SENP inhibitors.

Authors:  Ikenna G Madu; Andrew T Namanja; Yang Su; Steven Wong; Yi-Jia Li; Yuan Chen
Journal:  ACS Chem Biol       Date:  2013-05-01       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.